LeMaitre Vascular recalled 10 Artegraft Collagen Vascular Grafts on August 25, 2025, due to incorrect labeling. The devices lack CE and UKCA marks and are missing essential patient information. No distribution occurred within the U.S., but the affected products were sent to Great Britain and Switzerland.
Devices were distributed with incorrect label without CE and UKCA mark, missing patient leaflet and patient implant card.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact LeMaitre Vascular, Inc. or your healthcare provider for instructions. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled models are AG630M, AG636M, AG730M, AG740M, and AG845M. These devices were distributed internationally, with no sales in the U.S. The expiration date for the grafts is July 28, 2027.
The Artegraft devices were labeled incorrectly, lacking the required CE and UKCA marks. Missing patient leaflets and implant cards can lead to improper use and potentially serious health risks.
There are no reported incidents or injuries associated with the recalled grafts. The recall is a proactive measure to ensure patient safety.
Patients and healthcare providers should cease use of the recalled grafts immediately. Contact LeMaitre Vascular, Inc. or your healthcare provider for further instructions.
For more information, contact LeMaitre Vascular at the telephone number provided in the recall notification. Additional details can be found at the FDA recall website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.